Predict your next investment

HEALTHCARE | Biotechnology
inmunebio.com

See what CB Insights has to offer

Stage

IPO | IPO

Total Raised

$3.34M

Date of IPO

2/4/2019

Market Cap

0.20B

Stock Price

18.62

About Inmune Bio

Inmune Bio is a clinical stage immune-oncology company focused on harnessing the innate immune system for the treatment and prevention of cancer. Its focus is on helping the patient's own natural killer cells (NK cells) attack residual disease - the cancer that is left after treatment with chemotherapy.

Inmune Bio Headquarter Location

1224 Prospect Street Suite 150

La Jolla, California, 92037,

United States

858-964-3720

Latest Inmune Bio News

INmune Bio, Inc. to Participate in the B. Riley Fall 2021 Best Ideas in Oncology Series

Sep 27, 2021

Date: Thursday, September 30, 2021 Time: 9:00am ET About INmune Bio, Inc. INmune Bio, Inc . is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for COVID-19 complications (Quellor™), cancer (INB03™), Alzheimer’s and Treatment Resistant Depression (Xpro™), and NASH (LIVNate™). The Natural Killer Cell Priming Platform includes INKmune™ aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation with components of the innate immune system. To learn more, please visit  www.inmunebio.com . Information about Forward-Looking Statements Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03™, Quellor™, XPro1595, LIVNate™, and INKmune™ are still in clinical trials or preparing to start clinical trials and have not been approved and there cannot be any assurance that they will be approved or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. INmune Bio Contact:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Inmune Bio

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Inmune Bio is included in 3 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

B

Biopharmaceuticals

5,880 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

C

Cancer

3,604 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Inmune Bio Patents

Inmune Bio has filed 1 patent.

The 3 most popular patent topics include:

  • Diabetes
  • Diseases of liver
  • Hepatology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/27/2018

Diabetes, Diseases of liver, Obesity, Inflammations, Hepatology

Application

Application Date

9/27/2018

Grant Date

Title

Related Topics

Diabetes, Diseases of liver, Obesity, Inflammations, Hepatology

Status

Application

Inmune Bio Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Inmune Bio Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.